Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ACTRIMS 2023 | Self-reported adherence and safety from the MASTER-2 & CLICK-MS studies of cladribine in MS patients

Emily Evans, MD, MBE, EMD Serono, Rockland, MD, discusses the results from a study evaluating the treatment patterns, adherence, and safety of cladribine in patients with relapsing forms of multiple sclerosis (MS) after suboptimal response to prior injectable, oral or infusion disease-modifying therapies (DMTs). A total of 233 patients treated with cladribine were included in the analysis: 63 switching from an injectable DMT enrolled in the CLICK-MS (NCT03933215) trial, 102 from an oral DMT, and 68 from an infusion DMT enrolled in the MASTER-2 (NCT03933202) study. Adherence and safety outcomes from these ongoing studies were broadly similar to other cladribine studies. Importantly, self-reported adherence to cladribine was high, and no new or unexpected safety findings were reported. This interview took place at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2023 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.